Novo Nordisk (NVO) has released an update.
Novo Nordisk has halted the phase 3 CLARION-CKD trial of ocedurenone due to its failure to meet the primary endpoint and will record a significant impairment loss of DKK 5.7 billion. This unforeseen financial setback is expected to negatively impact the company’s operating profit growth by approximately 6%. The company will reevaluate the potential of ocedurenone for other medical indications.
For further insights into NVO stock, check out TipRanks’ Stock Analysis page.
